Telix and Regeneron Strike Global Radiopharma Alliance in Precision Oncology Push

An announcement from Telix Pharmaceuticals ( (AU:TLX) ) is now available.

Telix Pharmaceuticals and Regeneron Pharmaceuticals have entered a strategic collaboration to co-develop and co-commercialize next-generation radiopharmaceutical therapies for solid tumors, combining Telix’s radiopharmaceutical development and manufacturing platform with Regeneron’s antibody discovery technologies and oncology portfolio. The 50/50 cost and profit-sharing deal covers four initial therapeutic programs backed by a US$40 million upfront payment to Telix, with options for additional programs and a flexible structure that allows Telix either to share commercialization economics or to receive substantial milestones and royalties, while the partners also plan joint development of radio-diagnostics to enhance patient selection and treatment monitoring, potentially strengthening both companies’ positions in precision oncology and the emerging targeted radiopharmaceuticals market.

The most recent analyst rating on (AU:TLX) stock is a Buy with a A$30.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.

More about Telix Pharmaceuticals

Telix Pharmaceuticals is a global biopharmaceutical company specializing in the development and commercialization of radiopharmaceuticals to address significant unmet medical needs in oncology and rare diseases. Headquartered in Melbourne with operations across North America, Europe, Brazil and Japan, Telix is dual-listed on the ASX and Nasdaq, positioning it to serve global markets for precision radiopharma diagnostics and therapies.

YTD Price Performance: 30.71%

Average Trading Volume: 3,205,865

Technical Sentiment Signal: Buy

Current Market Cap: A$4.96B

See more data about TLX stock on TipRanks’ Stock Analysis page.